Clinical Trials Sponsored by Weikai Hou

Total 1845 results

Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Eisai Inc.

Completed

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Epilepsy, Complex Partial

United States, Estonia, Ukraine, Hungary, Lithuania
Eisai Inc.

Completed

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Leukemia

United States
Eisai Inc.

Suspended

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

Cancer

United States
Eisai Inc.

Completed

GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting

Intubation | Respiration, Artificial | Postoperative Sedation

United States
Eisai Inc.

Completed

A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

Kidney Neoplasms | Carcinoma, Renal Cell | Adenocarcinoma, Renal Cell

United States, France
Ly Hoa Anh Minh

Recruiting

Impact of Hepatitis B Virus Genotype on Treatment Response in Children With Chronic Hepatitis B

Chronic Hepatitis b

Vietnam
Biao Zou

Recruiting

Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders (FGIDs)

Functional Gastrointestinal Disorders

China
Biao Zou

Recruiting

Fecal Microbiota Transplantation in Pediatric Crohn's Disease (FMT)

Crohn Disease

China
True You Weight Loss

Active, not recruiting

ABLATE WEIGHT (Ablation Plus ESG for Weight Loss)

Obesity

United States
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Eisai Inc.

Completed

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Eisai Inc.

Active, not recruiting

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Breast Neoplasms | Receptors, Estrogen | Genes, Erbb-2

United States, United Kingdom
Eisai Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants

Healthy Volunteers

United States
Eisai Inc.

Completed

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Epilepsy

United States, Latvia
Eisai Inc.

Completed

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Cancer, Breast | Breast Cancer Female | Estrogen Receptor Positive Tumor | Breast Adenocarcinoma | ER Positive | Estrogen-receptor Positive Breast Cancer

France, United Kingdom, United States
Eisai Inc.

Completed

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Lymphoma, T-cell, Peripheral | Lymphoma, T-cell, Cutaneous

Japan
Eisai Inc.

Completed

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Breast Cancer | Estrogen Receptor Positive Tumor

United States
Eisai Inc.

Completed

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Advanced Solid Tumors

Netherlands, United Kingdom
Eisai Inc.

Completed

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Breast Cancer

United States
Eisai Inc.

Completed

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Breast Cancer

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Obesity

United States
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain
Eisai Inc.

Completed

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Solid Tumors

Japan
Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
Eisai Inc.

Completed

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Ewing Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma | Relapsed/Refractory Rhabdomyosarcoma

United States
Eisai Inc.

Completed

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, Spain, France, Germany, Italy, Japan, United Kingdom
Eisai Inc.

Completed

Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors

Liver Cancer

France
Eisai Inc.

Completed

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Eisai Inc.

Completed

Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)

Postoperative Nausea and Vomiting

United States
Eisai Inc.

Terminated

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

Photosensitive Epilepsy

United States
Eisai Inc.

Completed

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Thyroid Cancer

United States, Australia, France, Poland, United Kingdom, Italy
Eisai Inc.

Terminated

Study of E7046 in Subjects With Selected Advanced Malignancies

Tumors

United States, France
Eisai Inc.

Completed

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (SUNRISE 1)

Insomnia

United States, Spain, United Kingdom, Italy, Germany, France, Canada
Eisai Inc.

Completed

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Insomnia

United States
Eisai Inc.

Completed

A Food-Effect Study of E7386 in Healthy Participants

Food Effect in Healthy Participants

United States
Eisai Inc.

Completed

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Stage IV Melanoma | Unresectable Stage III

United States, United Kingdom, Australia, Germany
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States
Eisai Inc.

Completed

Safety and Efficacy of APD356 in the Treatment of Obesity

Obesity

United States
Eisai Inc.

Completed

Safety and Efficacy of APD356 in the Treatment of Obesity

Obesity

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Eisai Inc.

Completed

Trial of Decitabine in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Poland, Australia, Spain, France, Canada, Mexico, Romania, Taiwan, Russian Federation, Hungary, Serbia, Croatia, United Kingdom, Czechia
Eisai Inc.

Completed

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

HER2-normal

United States
Eisai Inc.

Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

France, Poland, United States, South Africa, Italy, Canada, Greece
Eisai Inc.

Completed

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Epilepsy

United States, Poland, Belgium, India, Korea, Republic of, Thailand, Hungary, Latvia, Czechia, Australia, Spain
Eisai Inc.

Completed

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Epilepsy

United States
Eisai Inc.

Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Metastatic Renal Cell Carcinoma

United States, Poland, United Kingdom, Spain, Czechia

3

Subscribe